Focus: CRISPR Therapeutics is a Boston-based biotechnology company pioneering CRISPR-Cas9 gene therapy for serious diseases including blood disorders, cancers, autoimmune conditions, and metabolic diseases. The company operates at the forefront of gene editing, with multiple clinical-stage programs targeting high-unmet-need indications.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Strong opportunity for gene therapy and cell therapy specialists seeking early-stage risk/reward in a platform-driven biotech with credible Phase 3 catalysts; avoid if you require revenue stability or mature commercial infrastructure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CRISPR Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CRISPR Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition - The Manila Times
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition The Manila Times
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates - TradingView
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates TradingView
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer - markets.businessinsider.com
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer markets.businessinsider.com
Eight product launches are part of the experience CRISPR Therapeutics' new technical chief brings. - Stock Titan
Eight product launches are part of the experience CRISPR Therapeutics' new technical chief brings. Stock Titan
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More - The Motley Fool
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More The Motley Fool
CRISPR Therapeutics Announces Chief Financial Officer Transition - markets.businessinsider.com
CRISPR Therapeutics Announces Chief Financial Officer Transition markets.businessinsider.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo